Table 5.
MDR features of S . Concord
| Author | MDR profiles | No. (%) |
|---|---|---|
| [13]a |
Amp Chl Cro Gen Sxt |
41(48.8) |
| Amp Chl Cro Gen Sxt Tet |
29(34.5) |
|
| Amp Chl Cro Gen Nal Sxt Tet |
5(6.0) |
|
| [14]b |
Amp Azt Chl (Cep Cfp Cfr Cft Cfz Cpo Cro Ctz ) Str SulTmp |
34(97.1) |
| |
Amp Azt Chl (Cep Cfp Cfr Cft Cfz Cpo Ctz ) Str SulTmp |
1(2.9) |
| [15]c |
Amp Chl Cro Gen Str Sul Sxt Tmp |
3(11.5) |
| Amp Chl Cro Gen Sul Str Sxt Tet Tmp |
19(73.1) |
|
| Amp Chl Cro Gen Nal Str Sul Sxt Tet Tmp |
4(15.4) |
|
| [41]d | Amp Chl Cfo Cro Gen Str Sul Tet Tmp | 8 (100) |
Amp = ampicillin; Azt = aztreonam; Cep = cephalothin; Cfo = cefotaxime; Cfp = cefepime; Cfr = cefuroxime; Cft = ceftiofur; Cfz = cefazolin; Cpo = cefpodoxime; Cro = ceftriaxone; Ctz = ceftazidime; Chl = chloramphenicol; Gen = gentamicin; Nal = nalidixic acid; Sul = sulfamethoxazole; Str = streptomycin; Sxt = co-trimoxazole; Tet = tetracycline; Tmp = trimethoprim.
aEach profile was recorded in more than 5% of the MDR isolates. One isolate was resistant to ofloxacin.
bResistance to gentamicin (97%), tetracycline (69%) and intermediate resistance to ciprofloxacin (14%) were recorded.
cSeven isolates showed intermediate resistance to ciprofloxacin.
dResistance to florfenicol (6/8), colistin (1/8) and intermediate resistance to ciprofloxacin (6/8) were recorded.